Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addres...

Source: BMC Clinical Pharmacology - October 29, 2019 Category: Drugs & Pharmacology Authors: Yang He, Jianhua Zhang, Guofang Shen, Lin Liu, Qingwei Zhao, Xiaoyang Lu, Hongyu Yang and Dongsheng Hong Tags: Research article Source Type: research